Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort

Nicholas F. Lahens1,2, Mahboob Rahman3, Jordana B. Cohen4,5, Debbie L. Cohen6, Jing Chen6, Matthew R. Weir7, Harold I. Feldman5, Gregory R. Grant1,8, Raymond R. Townsend1,4, Carsten Skarke1,2,4 and the CRIC Study Investigators*

Abstract
Patients with chronic kidney disease are at risk of developing cardiovascular disease. To facilitate out-of-clinic evaluation, we piloted wearable device-based analysis of heart rate variability and behavioral readouts in patients with chronic kidney disease from the Chronic Renal Insufficiency Cohort and controls (n = 49). Time-specific partitioning of heart rate variability readouts confirm higher parasympathetic nervous activity during the night (mean RR at night 14.4 ± 1.9 ms vs. 12.8 ± 2.1 ms during active hours; n = 47, analysis of variance (ANOVA) q = 0.001). The α2 long-term fluctuations in the detrended fluctuation analysis, a parameter predictive of cardiovascular mortality, significantly differentiated between diabetic and nondiabetic patients (prominent at night with 0.58 ± 0.2 vs. 0.45 ± 0.12, respectively, adj. p = 0.004). Both diabetic and nondiabetic chronic kidney disease patients showed loss of rhythmic organization compared to controls, with diabetic chronic kidney disease patients exhibiting deconsolidation of peak phases between their activity and standard deviation of interbeat intervals rhythms (mean phase difference chronic kidney disease 8.3 h, chronic kidney disease/type 2 diabetes mellitus 4 h, controls 6.8 h). This work provides a roadmap toward deriving actionable clinical insights from the data collected by wearable devices outside of highly controlled clinical environments.

Keywords
Heart rate variability, electrokardiogram, chronic kidney disease, diabetes, wearable devices, remote sensing, telemedicine, circadian phase, diurnal variability, outside of the hospital environment

Submission date: 23 February 2022; Acceptance date: 30 May 2022

1Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
2Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
3University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA
4Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
5Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
6Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
7Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
8Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Corresponding authors:
Nicholas F. Lahens, Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Email: nif@pennmedicine.upenn.edu
Carsten Skarke, Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Email: cskarke@pennmedicine.upenn.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Congestive heart failure (CHF) is the most common nonfatal FGFR cardiovascular (CV) morbidity seen in patients with CKD. Data collected from the Chronic Renal Insufficiency Cohort (CRIC) study have identified a number of factors associated with the development of CHF. These risk factors include arterial stiffness, elevated serum bicarbonate, increased pulse pressure (in CKD stages 4 and 5), and elevated levels of troponin T and NT-proBNP, as well as left ventricular hypertrophy on echocardiography. To date, these analyses have relied exclusively on data obtained through evaluations carried out on CRIC participants while in-center at yearly visits. However, the ability to measure biometric signals in ambulatory settings, and its acceptability in industry and academia, is expanding rapidly, and there are now several easy-to-use, wearable devices that record such signals. Furthermore, as health systems increase their use of telemedicine in response to the ongoing SARS-CoV-2 pandemic, remote sensing devices can help bridge a diagnostic gap between clinical settings and patients’ homes. Work in the preventive healthcare area currently employs biometric monitoring in the outpatient evaluation and management of heart failure. However, there is very little known about the prognostic value of biometric monitoring in CKD. Given the increasing emphasis on out-of-clinic health assessments, we conducted a biometric pilot study to evaluate the cardiovascular function and physical activity in CRIC study participants using a single wearable device, the Zephyr BioPatch. The BioPatch is a 2-lead cardiac monitoring device mounted on a patient’s sternum using adhesive tape patches.

We chose heart rate variability (HRV) as the parameter of interest to assess cardiovascular function as a prior report from the CRIC study showed an association between HRV and risk of mortality. In this previous study, Drawz et al. derived HRV data from 10 s of QRS complexes from a 12-lead electrocardiogram (EKG) from participants at rest during a clinic visit. HRV is defined as a group of parameters derived from waveform EKG tracings that evaluate the intervals between consecutive normal heartbeats as a proxy for autonomic nervous system function. In addition, arterial baroreflex function also influences HRV. Existing literature shows that cardiac autonomic function in patients with coronary artery disease (CAD), diabetes mellitus, existing CHF, and increasing age differs systematically from that of non-CAD patients. Both heart rate (HR) and its variability demonstrate robust endogenous circadian rhythms with sexually dimorphic effect sizes, an age-dependent decrease, and possibly seasonal differences. Notably, previous experiments showed subjects exhibit a reduced HRV under conditions of an evoked inflammatory response.

Progression of CKD tracks with a decrease in physical function in patients under pre-dialysis conditions and is associated with all-cause mortality and reduced quality of life. The National Health and Nutrition Examination Survey (NHANES) III estimated that physical inactivity was more prevalent among CKD patients (28%) than among non-CKD controls (13.5%); however, a limitation is the insignificant discriminatory impact on mortality in this questionnaire-based observational study. A Cochrane review emphasizes the beneficial effects of regular increased physical activity on risk factors in patients with CKD which led to refined exercise recommendations for this patient population. However, data on the level of physical activity maintained in the home environment of CKD patients are not routinely assessed.

The aim of the present two-center pilot study within the CRIC and an external reference cohort of healthy controls was to determine acceptance of wearable biosensor technology among participants and to discern whether data streams are associated with disease phenotypes, despite the noise introduced by activities of daily life, to generate clinical insight.

Results

Study participants

The CRIC study is an observational study that examined risk factors for the progression of chronic renal insufficiency (CRI) and CVD among CRI patients. For this subprotocol, the University of Pennsylvania and University Hospitals of Cleveland centers recruited n = 39 patient volunteers from the CRIC cohort with the following characteristics: 14 females (36%), 63.9 ± 7.7 years of age, 17 African-American, and 22 Caucasian (Supplementary Figure S1, Supplementary Table S1). Comorbidities included hypertension (33/39), type 2 diabetes mellitus (18/39; T2DM), asthma (8/39), chronic obstructive pulmonary disease (COPD) (6/39), and arthritis (3/39); but the degree of heterogeneity driven by medical history, prescription drugs, and laboratory tests is much higher, as listed in Supplementary Table S3. We leveraged the near balanced distribution of T2DM among CKD patients to address the hypothesis that biometric signals can differentiate between patients comorbid for CKD and T2DM (n = 18; labeled CKD/T2DM for the remainder of this manuscript) compared to CKD patients (n = 21) and controls (n = 10, Supplementary Figure S1). In clinical and laboratory assessments, CKD/T2DM patients (n = 21, estimated glomerular filtration rate (eGFR) of 55.1m2 ± 26.7m2 and HbA1c of 7.4% ± 1.2%) displayed lower glomerular filtration rate (GFR) compared to CKD patients (n = 18, eGFR
of 59.9 m² ± 22.9 m² and HbA1c of 5.6% ± 0.3%),(Supplementary Figure S3, Supplementary Table S2). On average, controls were younger than the cases (seven females, 30.4 ± 10.5 years of age, eight Caucasian, and two Asian, Supplementary Table S1), an approach that increased the likelihood to detect differences between cases and controls in cardiovascular-behavioral outputs.

**High degree of compliance and data quality for biometric data streams**

On average, CRIC participants wore the device for 49 ± 12.8 h and healthy controls for 48.3 ± 6.7 h. Variable wear times resulted from charging the device in the CRIC cohort, switching between devices in the controls, or personal reasons (e.g. shower breaks) in both cohorts (Supplementary Figure S2). Data from two CRIC participants showed a low level of compliance (wear time of 1.9 and 9.1 h). As a result, we excluded these two subjects from all BioPatch analyses. Data from the majority of participants (48/49) showed a high proportion of reliable HR readings (78.1 ± 16.8%), defined as HR confidence >20% provided in the BioPatch readouts. High correlations within subjects for time and frequency domain readouts underscore internal consistency for these time series. This is evident, for example, between standard deviation of normal-to-normal (SDNN) compared to total power (R² ≥ 0.6) and powers of high frequency (HF) (R² ≥ 0.73) as well as low frequency (LF) (R² ≥ 0.44); or root mean square of successive differences between normal heartbeats (RMSSD) compared to SD1 (R² = 1, Supplementary Figure S9). One CRIC participant showed particularly noisy EKG signals where HR confidence was below the 20% threshold during night hours (1.4 ± 1.1%). Taken together, these data suggest that the BioPatch is well suited to collect cardiovascular data under outpatient conditions.

**Biometric data differentiate day versus night**

To assess the internal validity of our dataset, we were interested to see if this biometric sampling approach can differentiate between day (06:00–22:00) and night (22:00–06:00) hours. As expected, day versus night differences in the BioPatch data streams were most pronounced in activity (0.06 ± 0.02 g vs. 0.002 ± 0.01 g; n = 47, ANOVA q = 1.3 × 10⁻¹⁷), peak acceleration (0.13 ± 0.04 g vs. 0.06 ± 0.01 g; n = 47, ANOVA q = 2.9 × 10⁻¹⁷), HR (68.6 ± 12.7 bpm vs. 55.2 ± 16 bpm; n = 47, ANOVA q = 6.3 × 10⁻⁹), breathing rate (14.4 ± 1.9 bpm vs. 12.8 ± 2.1 bpm; n = 47, ANOVA q = 0.001), and core temperature (37.02 ± 0.34°C vs. 36.7 ± 0.48°C; n = 47, ANOVA q = 3.2 × 10⁻⁵). To put the activity and acceleration data into context, commercial airline passengers experience an additional 0.1–0.3 force of gravity during takeoff, so that above stated levels may correspond more to the much slower acceleration of a train. The difference in posture (−26.6 ± 22.6° and −36.6 ± 37.1° for day vs. night, where values toward 0 indicate vertical posture and negative values indicate supine torso positions; n = 47) follows expectation (ANOVA p = 0.04, q = 0.18). The BioPatch-SDNN showed little diurnal difference with a high degree of variability (47.9 ± 23.2 ms vs. 50.4 ± 23.7 ms; n = 47, ANOVA p = 0.09, q = 0.25). These data are shown in Figure 1, Supplementary Tables S3 and S8.

We adopted the scientific-grade software Kubios to extend our HRV analyses (readouts are detailed in Supplemental material). In the Kubios HRV data, we found that the 250 Hz EKG waveform derived HR decreased at night (70 ± 23.7 bpm) compared to day (79.3 ± 18.8 bpm; n = 47, ANOVA p = 0.03, q = 0.14). Various HRV summary measures also showed an increase during night hours, as exemplified by mean RR (14.4 ± 1.9 ms vs. 12.8 ± 2.1 ms during active hours; n = 47, ANOVA q = 0.001) and RMSSD (53.7 ± 32.8 ms vs. 47.8 ± 32.5 ms; n = 47, ANOVA p = 0.07, q = 0.21). The Kubios-SDNN was comparable for day and night, 50.4 ± 24 ms versus 51.4 ± 24.1 ms, n = 47, ANOVA q = 0.54. Day versus night modulated the normalized spectral HRV for high frequency normalized unit (HFnu) (36.3 ± 13.1 vs. 42 ± 15.4; ANOVA q = 0.005) and low frequency normalized unit (LFnu) (63.6 ± 13.1 vs. 58 ± 15.4; ANOVA q = 0.005). These shifts indicated an increase in parasympathetic nervous activity throughout the night. The LF/HF ratio was lower at night (1.9 ± 1.6 vs. 2.2 ± 1.9; n = 47, ANOVA p = 0.04, q = 0.18). These metrics display findings in the fast Fourier transform (FFT) spectrum, and results for the autoregressive (AR) spectrum are similar. The nonparametric measure of autonomic nervous balance, the SD2/SD1 ratio, decreased from 2.1 ± 0.6 during the day to 1.7 ± 0.6 at night (ANOVA p = 0.04, q = 0.17). This appears to be the result of an increase in SD2 during the day (62.1 ± 26.2 ms vs. 61.36 ± 26.6 ms, ANOVA p = 0.007, q = 0.05) and an increase in SD1 during the night (33.8 ± 23 ms vs. 38 ± 23.2 ms, ANOVA p = 0.07, q = 0.21), though only the change in SD2 met our cutoff for statistical significance. Supplementary Tables S5 and S8 contain the complete summary output of the Kubios HRV analysis. Taken together, these data suggest that cardiovascular signals can be reliably collected through wearable technology in the natural settings of the participants’ individual conditions.

**Biometric phenotypes track with health condition**

Next, we sought to examine whether the biometric signals can differentiate between CKD and CKD/T2DM (CKD patients comorbid with type II diabetes mellitus) patients compared to controls, despite the noise introduced by sampling in the wild, confounding co-morbidities, and therapeutic management. Here, we addressed this using a...
two-way ANOVA (with Benjamini–Hochberg correction) to test for differences in biometric signals across cohort and time of day, followed by post hoc Tukey tests. Phenotypic differences among cohorts are most pronounced for activity (ANOVA \( q = 9.6 \times 10^{-5} \)) and peak acceleration (ANOVA \( q = 0.0003 \)) and emergent for BioPatch-SDNN (ANOVA \( p = 0.01, q = 0.079 \)). Post hoc tests indicate this significant difference between cohorts for activity is largely driven by the divergence between CKD versus control (adj. \( p = 4.7 \times 10^{-5} \)) and CKD/T2DM versus control (adj. \( p = 9.8 \times 10^{-13} \)).

Furthermore, by looking at the interactions between cohort and time of day, we find the differences between the controls and CRIC patients are significant during the day (adj. \( p = 3.8 \times 10^{-8} \) for CKD and adj. \( p = 2 \times 10^{-12} \) for CKD/T2DM), but not at night (adj. \( p = 0.99 \) for CKD and adj. \( p = 0.94 \) for CKD/T2DM). The post hoc comparisons between CKD and CKD/T2DM did not achieve statistical significance (adj. \( p = 0.43 \)).

A similar pattern appears for peak acceleration with differences driven in the post hoc test by CKD or CKD/T2DM versus control (adj. \( p = 4.9 \times 10^{-8} \) and adj. \( p = 3.5 \times 10^{-8} \)).
10^{-11}$, respectively), pronounced during the day (adj. $p = 2 \times 10^{-7}$ and adj. $p = 2.5 \times 10^{-11}$, respectively) and absent at night. The BioPatch-SDNN trended toward a cohort-level difference (ANOVA $q = 0.079$) with differences between CKD/T2DM and controls (adj. $p = 0.008$) during both day (adj. $p = 0.024$) and night (adj. $p = 0.021$). The remaining BioPatch variables showed no significant differences between cohorts. Supplementary Table S6 provides the summary outputs.

The Kubios time-domain results identified several features trending toward significant differences between cohorts: mean HR (ANOVA $q = 0.143$), minimum HR (ANOVA $q = 0.142$), standard deviation of HR (ANOVA $q = 0.107$), and mean RR interval lengths (ANOVA $q = 0.165$) as listed in Supplementary Table S7. The numerical values in mean HR during the night showed directional differences with $83.5 \pm 27.3$ bpm for CKD/T2DM patients compared to $77.1 \pm 29$ bpm for CKD patients and $69.9 \pm 23.7$ bpm for controls. Similarly, the mean RR during the night was lowest for CKD/T2DM patients ($775.4 \pm 201.3$ ms) compared to CKD patients ($852.6 \pm 216.6$ ms) and controls ($915.2 \pm 191.9$ ms).

In the Kubios frequency domain results, the relative fast Fourier transformed very low frequency (% VLF, ANOVA $q = 0.027$) differed between cohorts (ANOVA $q = 0.079$) with differences between CKD/T2DM and controls (adj. $p = 0.008$) during both day (adj. $p = 0.024$) and night (adj. $p = 0.021$). The remaining Kubios variables showed no significant differences between cohorts. Supplementary Table S7 provides the summary outputs.

The BioPatch-SDNN trended toward a cohort-level difference (ANOVA $q = 0.079$) with differences between CKD/T2DM and controls (adj. $p = 0.008$) during both day (adj. $p = 0.024$) and night (adj. $p = 0.021$). The remaining BioPatch variables showed no significant differences between cohorts. Supplementary Table S6 provides the summary outputs.

The Kubios time-domain results identified several features trending toward significant differences between cohorts: mean HR (ANOVA $q = 0.143$), minimum HR (ANOVA $q = 0.142$), standard deviation of HR (ANOVA $q = 0.107$), and mean RR interval lengths (ANOVA $q = 0.165$) as listed in Supplementary Table S7. The numerical values in mean HR during the night showed directional differences with $83.5 \pm 27.3$ bpm for CKD/T2DM patients compared to $77.1 \pm 29$ bpm for CKD patients and $69.9 \pm 23.7$ bpm for controls. Similarly, the mean RR during the night was lowest for CKD/T2DM patients ($775.4 \pm 201.3$ ms) compared to CKD patients ($852.6 \pm 216.6$ ms) and controls ($915.2 \pm 191.9$ ms).

In the Kubios frequency domain results, the relative fast Fourier transformed very low frequency (% VLF, Supplementary Table S7), proposed among other HRV features to predict survival in patients with myocardial infarction, differed between cohorts (ANOVA $q = 0.045$). This was driven by the divergence between controls and CKD/T2DM patients (adj. $p = 0.005$) for both day ($13 \pm 4.9$ and $18.3 \pm 7.4$, respectively) and night ($13.3 \pm 4.6$ and $18.9 \pm 9.7$, respectively). The relative, AR modeled VLF showed a trend toward significant divergence between cohorts (ANOVA $q = 0.142$), potentially driven by the comparison of controls to CKD/T2DM patients (adj. $p = 0.037$, Supplementary Table S7).

The EKG-derived respiration (EDR) in the fast Fourier transformed metrics (Supplementary Table S7) was different between cohorts (ANOVA $q = 5 \times 10^{-5}$). Here, both sets of CKD patients diverged significantly from controls during day ($0.23 \pm 0.04$ in CKD and $0.22 \pm 0.06$ in CKD/T2DM vs. $0.3 \pm 0.05$ in controls, adj. $p = 8.4 \times 10^{-7}$ and adj. $p = 3.2 \times 10^{-8}$, respectively) and night ($0.23 \pm 0.05$ in CKD and $0.22 \pm 0.06$ in CKD/T2DM vs. $0.28 \pm 0.06$ in controls, adj. $p = 0.007$ and adj. $p = 0.0002$, respectively). The natural logarithmically transformed absolute powers of high and low-frequency bands trended toward differences across cohorts (ANOVA $q < 0.18$ and ANOVA $q < 0.14$, respectively, for both parametric AR modeling and FFT). Post hoc tests suggest an emerging difference between controls and CKD/T2DM patients (adj. $p < 0.012$ for both transformations, Supplementary Table S7).

Among the Kubios nonlinear results, the dimensionless $\alpha_2$ long-term fluctuations in the detrended fluctuation analysis ($\alpha_2$-DFA) differed between cohorts (ANOVA $q = 0.02$). The post hoc test attributes this to the divergence between CKD and CKD/T2DM (adj. $p = 0.015$) during both the day ($0.5 \pm 0.13$ and $0.58 \pm 0.17$, respectively, adj. $p = 0.047$) and night ($0.45 \pm 0.12$ and $0.58 \pm 0.2$, respectively, adj. $p = 0.004$). $\alpha_2$-DFA also showed a significant difference between controls and CKD/T2DM patients (adj. $p = 0.034$) only during the night ($0.45 \pm 0.11$ and $0.58 \pm 0.2$, respectively, adj. $p = 0.034$). This is visualized in Figure 2. DFA assesses non-stochastic self-similarity by quantifying how current values in time series data are determined by their past values, a concept coined “long-memory” processes. Disease conditions, such as diabetes, and severe obstructive sleep apnea, have been associated with higher $\alpha_2$-DFA compared to controls. Importantly, increases in $\alpha_2$-DFA were associated with higher all-cause mortality in a Japanese cohort of about 300 septuagenarians and octogenarians. In the Framingham Heart Study, abnormal cardiac control quantified by a low “DFA index” and other HRV markers was associated with poor survival in a cohort of 69 septuagenarians with chronic CHF. Of note is that modulation of DFA by age did not emerge in 114 healthy volunteers.

![Figure 2. $\alpha_2$ long-term fluctuations in detrended fluctuation analysis ($\alpha_2$-DFA). Boxplot with mean values for the Kubios heart rate variability (HRV) readout, $\alpha_2$-DFA, are shown for all participants (black dots) as well as for CKD/T2DM patients (green dots), CKD patients (orange dots), and healthy volunteers (blue dots) including day versus night differences. CKD, chronic kidney disease; T2DM, type 2 diabetes mellitus.](image-url)
The correlation dimension D2, a nonlinear HRV feature shown to decrease under acute stress conditions in students\textsuperscript{34} and lower in patients with dilated cardiomyopathy (DCM) compared to controls,\textsuperscript{35} discriminated well between cohorts (ANOVA q = 0.001). Here, controls (2.5 ± 1.6 during day; 2.48 ± 1.54 during night) differ from CKD (adj. p = 0.001) and CKD/T2DM (adj. p = 1.5 × 10^{-6}), most prominently during the day (1.05 ± 1.27, adj. p = 0.004 and 0.58 ± 0.93, 5.5 × 10^{-6}, respectively) and less so during the night (1.33 ± 1.29, adj. p = 0.06 and 0.94 ± 1.41, adj. p = 0.001, respectively). The CKD and CKD/T2DM patients failed to show a significant difference in correlation dimension D2 (adj. p = 0.26).

In summary, we conclude that phenotypic features composed of a subset of BioPatch data streams and Kubios HRV metrics differentiate between patients and controls. Given that these differences were driven largely by comparisons between CKD/T2DM patients and controls, as suggested by the post hoc tests, but not by differences between CKD patients and controls, it is possible that disease severity affects these relationships in addition to the expected age-related difference between patient and control cohorts. We also note that despite the abundance of parameters, a total of 62 HRV features, and correction for multiple testing, the α2-DFA emerges as a candidate marker to differentiate between CKD and CKD/T2DM cohorts in the present study.

**Loss of rhythmicity in patients**

In light of the observation in Figure 1 that diurnal changes in HRV are lost in a CKD/T2DM patient and dampened in a CKD patient compared to a healthy participant, and supported by prior evidence,\textsuperscript{11} we hypothesize that CKD patients have altered rhythm characteristics. We found a significant difference in the MESOR (rhythm-adjusted mean) of activity levels between cohorts (Bonferroni-Holm corrected ANOVA p = 1.5 × 10^{-5}), Supplementary Table S12). The post hoc tests suggest that controls are more physically active (0.057 ± 0.012 g) than patients with CKD (0.044 ± 0.026 g, adj. p = 5.2 × 10^{-5}) or CKD/T2DM (0.042 ± 0.007 g, adj. p = 1.6 × 10^{-6}). Note that CKD patients did not differ significantly from patients with CKD/T2DM (adj. p = 0.5). This difference in activity MESOR is potentially confounded by the age differences between the CRIC patients and the controls, and will require further investigation in future studies. Though the between-group differences are substantial for the MESOR of BioPatch-SDNN, lowest in CKD/T2DM patients (38.5 ± 23.6 ms) followed by CKD patients (48 ± 18.9 ms) and controls (62.5 ± 14.1 ms), only the comparison between controls and CKD/T2DM patients attained significance (Bonferroni-Holm corrected ANOVA p = 0.01). Differences in MESOR for breathing and HR were less pronounced, as shown in Figure 3. The mean amplitude of activity was higher in controls (0.033 ± 0.011 g) compared to both CKD (0.023 ± 0.01, Bonferroni-Holm corrected ANOVA p = 0.03) and CKD/T2DM (0.022 ± 0.007, Bonferroni-Holm corrected ANOVA p = 0.01) patients, respectively. Statistically, the two patient groups did not differ (Bonferroni-Holm corrected ANOVA p = 0.9) from each other. Amplitudes for breath, HR, and SDNN failed to show a significant difference between cohorts.

We observed negligible divergence in the acrophases (peak times) of activity across the three cohorts, with all subjects peaking between 14:30 and 15:00 in the afternoon, with a consistent error of 1–2 h in each cohort. This is likely because all the subjects were entrained to similar light–dark schedules. Breathing and HR show similar acrophases, though the variability in CKD/T2DM and CKD patients is much higher than in controls, which might be reflective of the loss of rhythmicity in these patients. In contrast, the mean acrophase of SDNN occurs much earlier in the day, at around 08:30 for CKD/T2DM patients compared to 06:20 for CKD patients and 08:00 for controls. Again, we observe increased variability in SDNN acrophases among CKD patients, as shown in Figure 3. Supporting data is shown in Supplementary Table S11.

Overall, these data suggest that the diurnal rhythmicity of CKD patients is dampened relative to controls.

**Phase relationships deconsolidate in patients**

Next, by comparing the acrophases across different physiological data streams (like activity and SDNN) within each subject, we sought to assess whether disease states can alter or disrupt an individual’s circadian organization. This is similar to a previous study that found shift work decreased the acrophase angle between HRV readouts and physical activity.\textsuperscript{36} Using the acrophase of physical activity as a reference in the present study (Supplementary Figure S8), we calculated the within-subject differences between the acrophase of activity, and the acrophases of breathing rate, HR, and BioPatch-SDNN. The healthy controls showed minimal differences for both breathing rate (1 h, i.e. Cosinor PhaseActivity of 14.9 h vs. Cosinor PhaseBR of 15.9 h in Supplementary Table S10) and HR (0.6 h), but a substantial difference for the BioPatch-SDNN (mean phase difference of 6.8 h). CKD and CKD/T2DM patients showed similar acrophase differences between activity and breathing or HR. Notably, the difference in acrophase between activity and BioPatch-SDNN showed a substantial amount of variability in CKD (mean phase difference of 8.3 h) and CKD/T2DM patients (mean phase difference of 4 h) compared to healthy controls, as shown in Supplementary Figure S8, left. To address the concern that loss of rhythmicity may confound the cosinor determination of acrophases, we applied a more stringent weighted smoothing method, LOESS, to confirm the results as shown in Supplementary Figure S8, right and Supplementary Table S10. Strikingly, the dispersion of acrophases of BioPatch-SDNN spans the entire 24-hour range shown in...
Supplementary Figure S8, suggesting deconsolidation of acrophase differences among the CKD/T2DM patients, in particular.

Altered circadian organization of biometric variables in CKD patients

In an effort to define ways to condense the data streams from the BioPatch and the Kubios HRV analysis, we applied the following strategy. First, we constructed a variance correlation matrix to capture how the observed variability is shared among pairs of biometric variables. This measures the proportion of variance observed in one variable that can be explained by the variance observed in another variable. This, in a way, examines circadian organization among biometric variables in that two variables with similar temporal patterns should be highly correlated over time. This could offer insight in whether two sinusoids, i.e. variables with diurnal variability, are synchronous, meaning the shape over time is similar with a shared acrophase. In contrast, two sinusoids with different acrophases would barely correlate suggesting a desynchronized relationship over time. Thus, we used this metric to confirm expectations within domains, such as the high correlations between peak acceleration and activity ($R^2 = 0.95$, Bonferroni corrected $p < 0.001$, observed in all cohorts). While this increases our confidence in the validity of these biometric assessments, it also allows us to explore how the variance explained shifts between participants and cohorts. This is shown, for example, in Supplementary Figure S4 for the BioPatch-derived data streams on the individual and cohort levels. Across domain, we observed the expected correlations between activity and HR ($R^2 = 0.22$, Bonferroni corrected $p < 0.001$), as well as activity and breathing rate ($R^2 = 0.15$, Bonferroni corrected $p < 0.001$) in controls. While this increases our confidence in the validity of these biometric assessments, it also allows us to explore how the variance explained shifts between participants and cohorts. This is shown, for example, in Supplementary Figure S4 for the BioPatch-derived data streams on the individual and cohort levels. Across domain, we observed the expected correlations between activity and HR ($R^2 = 0.22$, Bonferroni corrected $p < 0.001$), as well as activity and breathing rate ($R^2 = 0.15$, Bonferroni corrected $p < 0.001$) in controls. These correlations were lower in both CRIC patient cohorts for activity and HR ($R^2 = 0.10$, Bonferroni corrected $p < 0.001$), and for activity and breathing rate ($R^2 = 0.03$, Bonferroni corrected $p < 0.001$). HR and body core temperature correlated well in patients ($R^2 = 0.77$, Bonferroni corrected $p < 0.001$ in CKD/T2DM and $R^2 = 0.78$, Bonferroni corrected $p < 0.001$) compared to controls ($R^2 = 0.51$, Bonferroni corrected $p < 0.001$).
corrected \( p < 0.001 \), though the computational derivation of body core temperature from the HR signal may confound this. The high correlation between posture and sagittal acceleration likely reflects body movements in the sagittal plane from sitting down (\( R^2 = 0.71 \), Bonferroni corrected \( p < 0.001 \) in CKD/T2DM and \( R^2 = 0.79 \), Bonferroni corrected \( p < 0.001 \)) compared to controls (\( R^2 = 0.54 \), Bonferroni corrected \( p < 0.001 \)). The only correlation emerging for the BioPatch-SDNN is with HR (\( R^2 = 0.14 \), Bonferroni corrected \( p < 0.001 \) in CKD/T2DM and \( R^2 = 0.12 \), Bonferroni corrected \( p < 0.001 \) in CKD compared to controls \( R^2 = 0.11 \), Bonferroni corrected \( p < 0.001 \)).

Above, we calculated variance correlations from data we aggregated by cohort. We observe more drastic differences in these correlation patterns when we examine data from individual subjects. Comparing the two patients as shown in Figure 1, the CKD patient’s SDNN and HR correlate at \( R^2 = 0.12 \) (Bonferroni corrected \( p < 0.001 \)) while this is lost in the CKD/T2DM patient (\( R^2 = 0.01 \), Bonferroni corrected \( p < 0.001 \)). Similarly, correlations are weaker in the CKD/T2DM patient for HR and activity (\( R^2 = 0.11 \), Bonferroni corrected \( p < 0.001 \)), and for breathing rate and activity (\( R^2 = 0.09 \), Bonferroni corrected \( p < 0.001 \)) compared to the CDK patient (\( R^2 = 0.25 \), Bonferroni corrected \( p < 0.001 \) and \( R^2 = 0.30 \), Bonferroni corrected \( p < 0.001 \)). These findings suggest that this metric may be a feasible representation of biometric phenotypes.

Next, we used these \( R^2 \) values derived from the variance explained metric to generate a hierarchical cluster analysis of all subjects, exploring similarities between study participants in their biometric variables. While these clusters did not provide complete separation between the cohorts, we did observe clusters consisting predominantly of controls or a mix of CKD/T2DM and CKD patients (Supplementary Figure S5, top). These patterns naturally suggest a hypothesis for future studies to test: do the features captured by these clusters associate with disease risk or trajectory. For example, do the similarities shared by the single healthy volunteer (highlighted by the red arrow in Supplementary Figure S5, bottom) with the seven CKD/T2DM (green) and five CKD (orange) patients suggest a comparable risk profile? Or inversely, does the similarity between the single CKD (highlighted by the blue arrow in Supplementary Figure S5, bottom) patient and the five controls (blue) point toward a low risk for disease progression?

Many sources contribute to the variability observed in a dataset, particularly for data gathered outside of a controlled clinic. As a result, we sought to quantify how much of the overall variability in our data is contributed by temporal differences in biomeetric measurement versus inter-subject differences. Consequently, a biomeetric variable with a strong temporal pattern in a homogeneous cohort will have a much higher contribution of time to variance than inter-subject differences. This approach offers an opportunity to gauge, between cohorts, the disconnect of temporal relationships between biomelectric variables. This is visualized in Supplementary Figure S6 where the contribution of time to the observed variability in activity is consistently larger across all cohorts than the contribution to variance by inter-subject differences (green cluster below the diagonal line of identity as shown in Supplementary Figure S6). This underscores the strong temporal signal in activity. This is different for HR where only the controls show this pattern (blue data point below the line of identity as shown in Supplementary Figure S6). For breathing rate and BioPatch-SDNN, the contribution to variability is mostly driven by between-patient differences. Notably, the largest separation between cohorts occurred for SDNN where 49.5%, 36.1%, and 19.2% of the variances were contributed by inter-subject differences among CKD/T2DM patients, CKD patients, and controls, respectively. Complete time-versus-subject contribution to variance outputs are provided in Supplementary Table S9. Overall, this suggests that the behavioral (activity) phenotype, entrained by the light–dark cycle, is intact among all cohorts. However, rhythms in the cardiovascular (HR) phenotype appear to dampen in CKD/T2DM and CKD patients compared to controls.

Taken together, these data reduction strategies suggest the hypothesis that the circadian organization of biomelectric variables is altered in CKD patients and that this disruption is in part associated with disease state in CKD/T2DM versus CKD patients. Furthermore, these data demonstrate our ability to use wearable devices outside the clinical setting to detect significant alterations in physiological patterns.

Discussion

We undertook this study to test the feasibility of deriving actionable insight into HRV measures in patients with CKD under outpatient conditions. The range of cardiovascular responsiveness to the challenges of daily life is larger than in the clinic, where conventional EKG and HRV assessments are made. Clearly, the challenge is to discern signals from noise in the natural setting. This approach enables more robust inferences than if there were only a small number of observations per patient. In this pilot study, we observed that (i) the wearable device collects interpretable data in freely moving participants and that (ii) behavioral and cardiovascular parameters differed between day and night hours according to expectations. Among the BioPatch data streams and Kubios HRV metrics, only a subset of features passed the correction for multiple testing, highlighting the challenge that the number of parameters exceeded the sample size of participants in this study. The post hoc tests indicated that phenotypic divergence may be largest between CKD/T2DM patients compared to controls and much less between
CKD patients compared to controls. While this may represent the additive burden of risk-increasing co-morbidities, this may also be driven by the age difference between cases and controls in the present study. Notably in this context, a nonlinear parameter, i.e. $\alpha_2$-DFA, is significantly different between CKD and CKD/T2DM patients, suggesting this as a potential biomarker. Focusing on the diurnal patterns in the behavioral and cardiovascular phenotypes, our findings suggest that biorhythms are less robust in CRIC participants compared to controls and that phase relationships between HRV, heart/breathing rate, and physical activity may be deconsolidated among the CKD/T2DM patients, in particular. This latter finding is reminiscent of the abnormal acrophase differences between physical activity and the cardiac autonomous nervous system observed in rotating shift workers. This may translate into an increased risk of mortality. The MRos Sleep Study found a u-shaped association of mortality with rest-activity rhythms among older men with CVD. Patients with the most pronounced phase advance in peak activity (lowest quintile, 08:44–13:22 HH:mm) showed a substantially elevated mortality (a hazard ratio of 2.84 with a 95% confidence interval of 1.29–6.24) compared to the reference patients (middle quintile, 13:59–14:32 HH:mm). In contrast, patients with a phase delay (highest quintile, 15:09–23:30 HH:mm) seem to have a similar risk of mortality (a hazard ratio of 1.55 with a 95% confidence interval of 0.67–3.6) compared to the reference patients of the middle quintile.

We examined variability and temporal relationships by applying variance correlation, time-versus-subject-contribution-to-variance, and hierarchical clustering to transform the data from the present study guided by prior experience. The value of these preliminary data is to gain confidence in parsing mechanisms associated with disease expression in cohorts of patients and age- and sex-matched controls. Here, using the variances of the time-domain, (BioPatch-SDNN) as a marker, we estimate that sample sizes of $n = 5$ per cohort are required to detect a difference of 50 ms with 90% power at a significance threshold of 0.05. We confirmed these low sample sizes using the Kubios-SDNN, which resulted in $n = 8$ required per cohort to detect the same difference. This is inspired by the proposed thresholds associated with healthy conditions (SDNN >100 ms), compromised health (SDNN = 50–100 ms), unhealthy (SDNN < 50 ms), and cumulative survival after myocardial infarction. To account for differences in patients and technology, we recommend a more stringent power calculation. For instance, a sample size of $n = 44$ subjects per cohort would be required to detect a difference of 0.5 SD in SDNN with 90% power and a significance threshold of 0.05. Turning to $\alpha_2$ DFA, a sample size of $n = 12$ per cohort would detect a difference of 0.14 in $\alpha_2$ DFA with 90% power at a significance threshold of 0.05. This difference of 0.14 is reflective of the decreased parasympathetic modulation noted in diabetic patients compared to healthy controls. Based on the variance in our study, 44 subjects per cohort would be necessary to detect a difference of 0.5 SD in DFA $\alpha_2$. Notably, the range of $\alpha_2$ DFA values in our data (0.45–0.6) is much lower than the range listed in Roy and Ghatak (0.88–1.02), possibly owing to the different collection periods, 10 min in their study versus 2 days in the present study.

Biometric data provide insights into dynamic changes in vital signs, activity, and many other aspects of health. Recent advances in technology for remote capture of biometric data offer the opportunity to understand the effects that co-morbidities like CKD have on lifestyle in the places where patients live and move. The growing capacity to incorporate continuous electrocardiographic data, for example, can offer information on the prevalence of cardiovascular risk in this population that is not recorded in the confines of a brief office or research study visit. Since CKD is plagued by a higher age-related death rate, clear impairment of quality of life, and physical frailty, remotely captured biometric data will be useful to aid our understanding of how things like physical activity, short sleep duration, and vagaries in the circadian rhythm affect outcomes like death and further disability in the CKD population. Given the rise of cardiovascular complications and kidney injury among patients with COVID-19, telemedicine efforts should be paired with wearable biometric approaches to improve the clinical care space.

Methods

Study population

This two-center study enrolled a total of 39 patients without a diagnosis of atrial fibrillation, $n = 20$ at the University Hospitals of Cleveland Medical Center and $n = 19$ at the Hospital of the University of Pennsylvania, HUP.

Wearable device

This study used the Zephyr BioPatch (Zephyr Technology, Annapolis, MD, USA), distributed by Medtronic Corporation (Minneapolis, MN, USA). This research-grade wearable device records cardiovascular, respiratory, and behavioral data consistent with its FDA Class II clearance as a “physiological monitoring telemetry device intended for monitoring adults in the home, workplace and alternate care settings” (510(k) # K113045). This device has been deployed in the field, for example, to collect physiological monitoring of Chilean miners during the San Jose Mine rescue operation. In the present study, the target observational time for each patient was set to 48 h to cover two consecutive 24 h circadian cycles in order to enhance the detection of biological rhythms. Patients received a plug-in charging cradle and were instructed to remove the
BioPatch device (white “puck”) from its chest-mounted holder after approximately 24 h of use to recharge the device for approximately two hours followed by inserting it back into the BioPatch holder on the chest for continued recordings. Positioning of the two EKG snap electrodes to hold the BioPatch holder in place followed standard EKG guidelines for V1 and V2, i.e. V1 corresponds to the right fourth intercostal space; and V2 corresponds to the left fourth intercostal space. Prior to application of the snap electrodes skin was cleaned with rubbing alcohol and shaved if necessary. Healthy controls received two BioPatch devices and were trained and instructed to exchange the first by the second device after 24 h.

**Biomedical informatics**

EKG recordings were analyzed in 1-hour increments in Kubios HRV Premium (ver. 3.0, Kubios Team, Kuopio, Finland) to obtain time-of-day-dependent measures of HRV. Custom Perl and R code (GitHub, “WearablePhenotypingCRIC”) formatted these data and integrated them with BioPatch data streams for HR, breathing rate, breathing waveform, posture, accelerometry, and peak/minimum acceleration. In addition to summary statistics for cohort and time-of-day (wake vs. sleep hours), data were parsed (i) by cosinor analysis to obtain the rhythmic parameters amplitude and phase, (ii) by two-way ANOVA analysis and post hoc Tukey test corrected for multiple testing with the Benjamini–Hochberg method to discover significant associations, and (iii) by methods reducing data dimensionality to uncover meaningful relationships. Detailed descriptions are provided in Supplemental material.

**Acknowledgments:** We are indebted to our volunteers who consented to participate in this pilot study as well as to Angela Sheridan. Parts of this study were presented by C.S. at the Gordon Research Conference on Chronobiology, 23–28 June 2020, Spain.

**Contributorship:** N.F.L. created visualizations and worked on statistical analysis, biomedical informatics, data interpretation, writing, manuscript revision, visualizations, figures, and tables. M.R. executed literature search, study design, regulatory science, data collection, and manuscript revision. J.B.C., D.L.C., I.C., M.R.W., and G.R.G. worked on data analysis, data interpretation, and manuscript revisions. R.R.T. conducted literature search and worked on study design, regulatory science, study conduct, data collection, data analysis, data integration, data interpretation, writing, visualizations as well as figures and tables.

**Declaration of Conflicting Interests:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval:** Ethics approval for the addendum to the CRIC clinical study protocol (Penn IRB#707819) was granted by the Institutional Review Board of the University of Pennsylvania (Federalwide Assurance FWA00004028; IRB Registration: IORG0000029) and by the UH Cleveland Medical Center (Federalwide Assurance 00003937; IRB Registration: 02-03-04) in compliance with the guidance issued by the International Conference on Harmonization (ICH) harmonized tripartite guidelines: E6 Guideline for Good Clinical Practices (ClinicalTrials NCT00341448). For the control group, n = 10 healthy volunteers were recruited under Penn IRB#828728 at the Institute for Translational Medicine and Therapeutics, University of Pennsylvania (ClinicalTrials NCT03406351).

**Funding:** The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for the CRIC study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902, and U24DK060990). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/NCCR UCSF-CTSI UL1 RR-024131, Department of Internal Medicine, and University of New Mexico School of Medicine Albuquerque, NM R01DK119199.

Dr Skarke is the Robert L. McNeil Jr. Fellow in Translational Medicine and Therapeutics. Enrollment of the healthy control group was supported by a pilot project grant awarded to C.S. by the Center of Excellence in Environmental Toxicology (CEET) as part of the P30 EHSCC grant (P30-ES013508).

**Guarantor:** The guarantor for this work is C.S.

**Informed consent:** Not applicable, because this article does not contain any studies with human or animal subjects.

**ORCID iD:** Carsten Skarke https://orcid.org/0000-0001-5145-3681
**Trial registration:** Not applicable, because this article does not contain any clinical trials.

**Supplemental material:** Supplemental material for this article is available online.

**References**

1. Chirinos JA, et al. Arterial stiffness, central pressures and incident hospitalized heart failure in the chronic renal insufficiency cohort (CRIC) study. *Circ.Heart Fail.* 2014; 7: 709–716.
2. Dobre M, et al. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. *J Am Heart Assoc* 2015; 4: 1–10. doi:10.1161/JAHA.114.001599
3. Bansal N, et al. Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. *Kidney Int* 2016; 90: 1348–1356.
4. Dubin RF, et al. Associations of conventional echocardiographic measures with incident heart failure and mortality: the chronic renal insufficiency cohort. *Clin J Am Soc Nephrol* 2017; 12: 60–68.
5. Sun Y, Zhang M, Sun Z, et al. Demographic analysis from biometric data: achievements, challenges, and new frontiers. *IEEE Trans Pattern Anal Mach Intell* 2017; 40: 332–351. doi:10.1109/TPAMI.2017.2669035
6. Romano MF, et al. The informative contribution of the “virtual medical visit” in a new heart failure telemedicine integrated system. *Telemed J E Health* 2014; 20: 508–521.
7. Wieringa FP, Broers NJH, Kooman JP, et al. Wearable sensors: can they beneﬁt patients with chronic kidney disease? *Expert Rev Med Devices* 2017; 14: 505–519.
8. Drawz PE, et al. Heart rate variability is a predictor of mortality in chronic kidney disease: a report from the CRIC study. *Am J Nephrol* 2013; 38: 517–528.
9. Aysin B and Aysin E. Effect of respiration in heart rate variability (HRV) analysis. *Conf Proc IEEE Eng Med Biol Soc* 2006; 1: 1776–1779.
10. Casolo GC, et al. Heart rate variability during the acute phase of myocardial infarction. *Circulation* 1992; 85: 2073–2079.
11. Vinik AI, Freeman R and Erbas T. Diabetic autonomic neuropathy. *Semin Neurol* 2003; 23: 365–372.
12. Casolo G, Balli E, Taddei T, et al. Decreased spontaneous heart rate variability in congestive heart failure. *Am J Cardiol* 1989; 64: 1162–1167.
13. Umetani K, Singer DH, McCrory R, et al. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. *J Am Coll Cardiol* 1998; 31: 593–601.
14. Vandewalle G, et al. Robust circadian rhythm in heart rate and its variability: influence of exogenous melatonin and photoperiod. *J Sleep Res* 2007; 16: 148–155.
15. Nunan D, Sandercock GR and Brodie DA. A quantitative systematic review of normal values for short-term heart rate variability in healthy adults. *Pacing Clin Electrophysiol* 2010; 33: 1407–1417.
16. Jandackova VK, Scholes S, Britton A, et al. Are changes in heart rate variability in middle-aged and older people normative or caused by pathological conditions? Findings from a large population-based longitudinal cohort study. *J Am Heart Assoc* 2016; 5: 1–13. doi:10.1161/JAHA.115.002365
17. Markov A, Solonin I and Bojko E. Heart rate variability in workers of various professions in contrasting seasons of the year. *Int J Occup Med Environ Health* 2016; 29: 793–800.
18. Godin PJ, et al. Experimental human endotoxemia increases cardiac regularity: results from a prospective, randomized, crossover trial. *Crit Care Med* 1996; 24: 1117–1124.
19. Alamili M, Rosenberg J and Gogenur I. Day-night variation in heart rate variability changes induced by endotoxaemia in healthy volunteers. *Acta Anaesthesiol Scand* 2015; 59: 457–464.
20. Hiroki K, et al. Decreased physical function in pre-dialysis patients with chronic kidney disease. *Clin Exp Nephrol* 2013; 17: 225–231.
21. Roshanravan B, et al. Association between physical performance and all-cause mortality in CKD. *J Am Soc Nephrol* 2013; 24: 822–830.
22. Tsai YC, et al. Association of physical activity with cardiovascular and renal outcomes and quality of life in chronic kidney disease. *PLoS One* 2017; 12: e0183642.
23. Bzdhu S, Baird BC, Zitterkoph J, et al. Physical activity and mortality in chronic kidney disease (NHANES III). *Clin J Am Soc Nephrol* 2009; 4: 1901–1906.
24. Heiwe S and Jacobson SH. Exercise training for adults with chronic kidney disease. *Cochrane Database Syst Rev.* 2011; 10: CD003236. doi:10.1002/14651858.CD003236.pub2
25. Smart NA, et al. Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease. *J Sci Med Sport* 2013; 16: 406–411.
26. Aucella F, et al. Physical exercise programs in CKD: lights, shades and perspectives [corrected]. *J Nephrol* 2015; 28: 143–150.
27. Huikuri HV, et al. Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. *Circulation* 2000; 101: 47–53.
28. Sassi R, et al. Advances in heart rate variability signal analysis: joint position statement by the e-Cardiology ESC Working Group and the European Heart Rhythm Association co-endorsed by the Asia Pacific Heart Rhythm Society. *Europace* 2015; 17: 1341–1353.
29. Roy B and Ghatak S. Nonlinear methods to assess changes in heart rate variability in type 2 diabetic patients. *Arq Bras Cardiol* 2013; 101: 317–327.
30. da Silva EL, et al. Heart rate detrended fluctuation indexes as estimate of obstructive sleep apnea severity. *Medicine (Baltimore)* 2015; 94: e516.
31. Hotta N, et al. Fractal analysis of heart rate variability and mortality in elderly community-dwelling people – longitudinal investigation for the Longevity and Aging in Hokkaido County (LILAC) study. *Biomed Pharmacother* 2005; 59: S45–S48.
32. Ho KK, et al. Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. *Circulation* 1997; 96: 842–848.
33. Pikkujamsa SM, et al. Cardiac interbeat interval dynamics from childhood to senescence: comparison of conventional
and new measures based on fractals and chaos theory. 

*Circulation* 1999; 100: 393–399.

34. Melillo P, Bracale M and Pecchia L. Nonlinear heart rate variability features for real-life stress detection. Case study: students under stress due to university examination. *Biomed Eng Online* 2011; 10: 96.

35. Carvajal R, Wessel N, Vallverdu M, et al. Correlation dimension analysis of heart rate variability in patients with dilated cardiomyopathy. *Comput Methods Programs Biomed* 2005; 78: 133–140.

36. Yoshizaki T, et al. Diurnal 24-h rhythm in ambulatory heart rate variability during the day shift in rotating shift workers. *J Biol Rhythms* 2013; 28: 227–236.

37. Paudel ML, et al. Rest/activity rhythms and mortality rates in older men: MrOS sleep study. *Chronobiol Int* 2010; 27: 363–377.

38. Skarke C, et al. A pilot characterization of the human chronobiome. *Sci Rep* 2017; 7: 17141.

39. Kleiger RE, Miller JP, Bigger Jr JT, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* 1987; 59: 256–262.

40. Shaffer F and Ginsberg JP. An overview of heart rate variability metrics and norms. *Front Public Health* 2017; 5: 58.

41. Zephyr. Zephyr Provides Physiological Monitoring of Chilean Miners During San Jose Mine Rescue Operation. 2012. www.zephyranywhere.com. (2012, accessed 21 February 2022).

42. Hughes ME, et al. Guidelines for genome-scale analysis of biological rhythms. *J Biol Rhythms* 2017; 32: 380–393.